Amgen Inc (NASDAQ:AMGN) reported first-quarter (Q1) earnings Thursday, touting adjusted EPS of $3.96, which beat the analyst consensus estimate of $3.87. Here are highlights from the release and subsequent analyst call: Sales increased 22% Y/Y to $7.45 billion, which beat the analyst consensus estimate of $7.436 billion. Amgen sees full-year 2024 adjusted EPS of $19-$20.20 versus consensus of $19.48. The company is pulling the plug on AMG 786, an oral Phase 1 candidate for obesity, and remain focused on prioritizing differentiated medicines. Amgen CEO Robert Bradway said the company is “confident in MariTide’s differentiated profile and believe it will address important unmet medical needs.” Also Read: Sandoz Settles Patent Dispute With Amgen Related To ...